Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) CEO John Farquhar sold 35,010 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $46.42, for a total transaction of $1,625,164.20. Following the completion of the transaction, the chief executive officer directly owned 325,804 shares in the company, valued at $15,123,821.68. This trade represents a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
John C.M. Farquhar also recently made the following trade(s):
- On Friday, September 11th, John Farquhar sold 3,890 shares of Heartflow stock. The shares were sold at an average price of $50.00, for a total value of $194,500.00.
- On Friday, August 21st, John Farquhar sold 27,230 shares of Heartflow stock. The shares were sold at an average price of $50.00, for a total value of $1,361,500.00.
- On Tuesday, August 18th, John Farquhar sold 32,676 shares of Heartflow stock. The stock was sold at an average price of $45.00, for a total value of $1,470,420.00.
- On Friday, August 14th, John Farquhar sold 15,560 shares of Heartflow stock. The shares were sold at an average price of $39.06, for a total value of $607,773.60.
- On Monday, August 10th, John Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.31, for a total value of $638,730.22.
- On Friday, July 10th, John Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.75, for a total value of $626,095.50.
- On Wednesday, June 24th, John Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00.
Heartflow Trading Down 0.1%
Shares of HTFL opened at $48.30 on Thursday. Heartflow, Inc. has a 12-month low of $20.13 and a 12-month high of $51.78. The firm has a 50-day moving average price of $36.83 and a 200 day moving average price of $31.38. The firm has a market capitalization of $4.20 billion and a P/E ratio of -26.39.
Wall Street Analyst Weigh In
Several research firms have issued reports on HTFL. Wells Fargo & Company raised their target price on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Piper Sandler restated an “overweight” rating and issued a $45.00 price objective (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. UBS Group initiated coverage on shares of Heartflow in a research note on Wednesday, September 9th. They set a “neutral” rating and a $55.00 target price for the company. Benchmark reissued a “buy” rating on shares of Heartflow in a research note on Friday, August 14th. Finally, Morgan Stanley increased their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and an average target price of $44.88.
Check Out Our Latest Stock Analysis on Heartflow
More Heartflow News
Here are the key news stories impacting Heartflow this week:
- Positive Sentiment: Heartflow’s latest quarterly results remain a fundamental positive: revenue increased 47.7% year over year to $64.08 million, while the $0.07-per-share loss was substantially better than the $0.22 loss analysts expected. Heartflow earnings information
- Positive Sentiment: Analyst sentiment is still broadly favorable, with a consensus “Moderate Buy” rating. UBS initiated coverage with a $55 price target, although the broader average target of $44.88 is below recent trading levels.
- Neutral Sentiment: Institutional interest has provided some support, including Squarepoint Ops increasing its position by 72% and several funds initiating new stakes during the second quarter.
- Negative Sentiment: CFO Vikram Verghese sold 34,975 shares for approximately $1.75 million between September 11 and September 15 at prices near $50. He still directly owns 179,528 shares, but the repeated sales reduce insider ownership and may concern momentum-focused investors. The transactions were conducted under a pre-arranged trading plan. CFO SEC filing
- Negative Sentiment: CEO John C.M. Farquhar sold 38,900 shares for roughly $1.82 million in transactions dated September 10–11. The sales occurred as Heartflow traded near its 52-week high, reinforcing concerns that executives are taking profits and likely contributing to the stock’s recent decline. Heartflow CEO share sale
- Negative Sentiment: Heartflow remains unprofitable, with a negative net margin and analysts expecting a full-year loss of approximately $0.75 per share. Its valuation and sharp rise above the 50-day and 200-day moving averages could increase sensitivity to profit-taking.
Hedge Funds Weigh In On Heartflow
A number of hedge funds and other institutional investors have recently bought and sold shares of HTFL. TrueMark Investments LLC increased its stake in Heartflow by 1.4% during the 1st quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock worth $654,000 after buying an additional 379 shares during the period. Strs Ohio boosted its position in Heartflow by 35.3% in the 1st quarter. Strs Ohio now owns 4,600 shares of the company’s stock valued at $112,000 after buying an additional 1,200 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Heartflow in the second quarter worth $53,000. Mayport LLC increased its position in shares of Heartflow by 20.0% during the second quarter. Mayport LLC now owns 12,000 shares of the company’s stock worth $352,000 after acquiring an additional 2,000 shares during the period. Finally, Essential Partners LLC purchased a new stake in shares of Heartflow during the first quarter worth $57,000.
Heartflow Company Profile
Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.
The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFRCT).
Further Reading
- Five stocks we like better than Heartflow
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
